Literature DB >> 24687188

Prognostic impact of admission blood glucose for all-cause mortality in patients with acute coronary syndromes: added value on top of GRACE risk score.

Ana T Timóteo1, Ana L Papoila2, Pedro Rio3, Fernando Miranda4, Maria L Ferreira3, Rui C Ferreira3.   

Abstract

BACKGROUND: Abnormal glucose metabolism is a predictor of worse outcome after acute coronary syndrome (ACS). However, this parameter is not included in risk prediction scores, including GRACE risk score. We sought to evaluate whether the inclusion of blood glucose at admission in a model with GRACE risk score improves risk stratification.
METHODS: Study of consecutive patients included in a single centre registry of ACS. Our primary endpoint was the occurrence of all-cause mortality at one-year follow-up. The ability of the two logistic regression models (GRACE risk score alone and in combination with blood glucose) to predict death was analysed. Continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI), with corresponding 95% confidence intervals (CIs), were also calculated.
RESULTS: We included 2099 patients, with a mean age of 64 (SD=13) years, 69% males. In our sample, 55.1% presented with ST-segment elevation ACS and 13.1% in Killip class ≥ 2. Only 25% were known diabetic at admission. In-hospital mortality was 5.8% and 9.7% at one-year follow-up. The best cut-point for blood glucose was 160 mg/dl (sensitivity 62% and specificity 68%), and 35.2% of the patients had increased levels. This group was elderly, had more prevalence of cardiovascular risk factors, worse renal function and GRACE score as well as more frequently Killip class ≥2. Treatment was similar in both groups besides less frequent use of clopidogrel in high glycaemic patients. The hyperglycaemia group had higher one-year mortality (17.2% vs. 5.6%, p<0.001). Moreover, binary blood glucose remained a predictor of death independently of the GRACE risk score and the presence of diabetes (odds ratio (OR) 1.99, 95% CI 1.40-2.84, p<0.001). The inclusion of blood glucose, as a continuous variable, in a logistic regression model with GRACE score, increased the area under the ROC curve from 0.80 to 0.82 (p=0.018) as well as the goodness-of-fit and was associated with an improvement in both the NRI (37%) and the IDI (0.021), suggesting effective reclassification.
CONCLUSIONS: A blood glucose level on admission ≥ 160 mg/dl is an independent predictor of mortality in medium-term follow-up. It offers an incremental predictive value when added to the GRACE risk score, although with a modest magnitude of improvement, probably due to the high predictive performance of the GRACE risk score alone. © The European Society of Cardiology 2014.

Entities:  

Keywords:  Admission blood glucose; GRACE risk score; acute coronary syndromes; prognosis

Mesh:

Substances:

Year:  2014        PMID: 24687188     DOI: 10.1177/2048872614528858

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  9 in total

Review 1.  Neuroendocrine System Regulatory Mechanisms: Acute Coronary Syndrome and Stress Hyperglycaemia.

Authors:  Ricardo A Perez de la Hoz; Sandra Patricia Swieszkowski; Federico Matias Cintora; Jose Martin Aladio; Claudia Mariana Papini; Maia Matsudo; Alejandra Silvia Scazziota
Journal:  Eur Cardiol       Date:  2018-08

2.  Admission Glucose Level Predicts In-hospital Mortality in Patients with Acute Pulmonary Embolism Who Were Treated with Thrombolytic Therapy.

Authors:  Mehmet Bozbay; Huseyin Uyarel; Sahin Avsar; Ahmet Oz; Muhammed Keskin; Ahmet Murat; Adnan Kaya; Halil Atas; Ahmet Altug Cincin; Murat Ugur; Mehmet Eren
Journal:  Lung       Date:  2016-02-19       Impact factor: 2.584

3.  Predictive performance of adding platelet reactivity on top of CRUSADE score for 1-year bleeding risk in patients with acute coronary syndrome.

Authors:  Shan Li; Hongbin Liu; Jianfeng Liu
Journal:  J Thromb Thrombolysis       Date:  2016-10       Impact factor: 2.300

4.  Combined Value of Red Blood Cell Distribution Width and Global Registry of Acute Coronary Events Risk Score for Predicting Cardiovascular Events in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Authors:  Na Zhao; Lan Mi; Xiaojun Liu; Shuo Pan; Jiaojiao Xu; Dongyu Xia; Zhongwei Liu; Yong Zhang; Yu Xiang; Zuyi Yuan; Gongchang Guan; Junkui Wang
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

5.  Comparison of the GRACE risk score and the TIMI risk index in predicting the extent and severity of coronary artery disease in patients with acute coronary syndrome.

Authors:  Adem Bekler; Burak Altun; Emine Gazi; Ahmet Temiz; Ahmet Barutçu; Ömer Güngör; Muhammed Turgut Alper Özkan; Sedat Özcan; Sabri Gazi; Bahadır Kırılmaz
Journal:  Anatol J Cardiol       Date:  2014-10-15       Impact factor: 1.596

6.  Admission hyperglycemia and adverse outcomes in diabetic and non-diabetic patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention.

Authors:  Yuanyuan Hao; Qun Lu; Tao Li; Guodong Yang; Peijing Hu; Aiqun Ma
Journal:  BMC Cardiovasc Disord       Date:  2017-01-05       Impact factor: 2.298

7.  Impact of hyperglycemia on myocardial ischemia-reperfusion susceptibility and ischemic preconditioning in hearts from rats with type 2 diabetes.

Authors:  Steen Buus Kristiansen; Kim Bolther Pælestik; Jacob Johnsen; Nichlas Riise Jespersen; Kasper Pryds; Marie Vognstoft Hjortbak; Rebekka Vibjerg Jensen; Hans Erik Bøtker
Journal:  Cardiovasc Diabetol       Date:  2019-05-31       Impact factor: 9.951

8.  Prognostic ability of cystatin C and homocysteine plasma levels for long-term outcomes in very old acute myocardial infarction patients.

Authors:  Zhenhong Fu; Xia Yang; Mingzhi Shen; Hao Xue; Geng Qian; Feng Cao; Jun Guo; Wei Dong; Yundai Chen
Journal:  Clin Interv Aging       Date:  2018-07-03       Impact factor: 4.458

9.  Risk Stratification for Patients with Chest Pain Discharged Home from the Emergency Department.

Authors:  Peter A Kavsak; Joshua O Cerasuolo; Shawn E Mondoux; Jonathan Sherbino; Jinhui Ma; Brock K Hoard; Richard Perez; Hsien Seow; Dennis T Ko; Andrew Worster
Journal:  J Clin Med       Date:  2020-09-12       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.